Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity.
A preterm infant with zone 1 aggressive posterior retinopathy of prematurity developed infectious endophthalmitis after intravitreal injection of ranibizumab. Urgent empirical intravitreal therapy with vancomycin, ceftazidime, and dexamethasone along with intravenous therapy with amikacin and meropenem helped in early resolution. Vascularization/activity of disease subsided on follow-up, media cleared, and laser photocoagulation was completed. Later the disease reactivated, developed vitreous membranes and central retinal traction, for which 25-gauge lens-sparing vitrectomy was performed. Emergent treatment helped in salvaging the eye from both aggressive ROP disease and devastating endophthalmitis. Rationale approach to such a case is being discussed.
['Chandra|Parijat|P|', 'Kumawat|Devesh|D|', 'Tewari|Ruchir|R|', 'Azimeera|Suresh|S|']
D020533:Angiogenesis Inhibitors D000900:Anti-Bacterial Agents D009877:Endophthalmitis D005500:Follow-Up Studies D006801:Humans D007231:Infant, Newborn D007275:Injections, Intravenous D058449:Intravitreal Injections D008297:Male D000069579:Ranibizumab D012178:Retinopathy of Prematurity D042461:Vascular Endothelial Growth Factor A
Endophthalmitis retinopathy of prematurity ranibizumab vascular endothelial growth factor